- Aduro Biotech merged with Chinook Therapeutics. The combined company operates as Chinook Therapeutics. (2020)
Aduro BioTech Inc is a United States-based clinical-stage immunotherapy company. The Company has developed or acquired technology platforms designed to activate potent and lasting immune responses against cancer: live, attenuated Listeria, GVAX and cyclic dinucleotides (CDNs). Aduro’s lead program is an immunotherapy regimen combining Listeria-based CRS-207 and GVAX Pancreas in patients with metastatic pancreatic cancer who have failed at least one therapy. Its pipeline includes CRS-207, ADU-623, ADU-214, ADU-741, CDN and STINGVAX. CRS-207 is based on Aduro’s Listeria platform. ADU-623 is Aduro's first clinical bivalent Listeria-based immunotherapy. ADU-214 is a bivalent Listeria-based immunotherapy that targets both mesothelin and an EGFR mutation. CDNs are small molecules that signal through STING and induce a potent immune response. STINGVAX is the combination of CDNs and GVAX.
Address
626 Bancroft Way Ste 3-C
BERKELEY, CA 94710-2224
United States
Key stats and ratios
|
| Net profit margin | -9.30% | -127.07% |
| Operating margin | -11.38% | -142.79% |
| EBITD margin | - | -141.00% |
| Return on average assets | -4.39% | -24.96% |
| Return on average equity | -7.19% | -47.17% |
| Employees | 50 |
No comments:
Post a Comment